News
Novo Nordisk, MAS
Digest more
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...
Pharmaceutical Technology on MSN1d
Wegovy becomes first GLP-1RA to gain FDA MASH approval
Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...
Health and Me on MSN22h
Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis
FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback